GH
Guardant Health, Inc. · Healthcare · Medical - Diagnostics & Research
Señales de momentum (gestores comparables):
amplitud de titulares +4.8% ·
flujo de acciones -4.7% ·
nuevas posiciones netas 0.0%
· fórmula
Fragmentación de la titularidad: más titulares, participación agregada más pequeña
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q3 2025
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 45.42K | $7.92M | n/a | n/a |
| Q2 2026 | 137 | +11 | 93.62M | $13.95B | +17 | −7 |
| Q1 2026 | 130 | -8 | 97.95M | $8.77B | +5 | −14 |
| Q4 2025 | 137 | +1 | 99.79M | $9.86B | +2 | n/a |
| Q3 2025 | 22 | +1 | 50.89M | $3.18B | +2 | −2 |
| Q2 2025 | 19 | -1 | 51.15M | $2.66B | n/a | −1 |
| Q1 2025 | 17 | -1 | 25.07M | $1.07B | n/a | −1 |
| Q4 2024 | 18 | +2 | 25.10M | $766.76M | +2 | n/a |
| Q3 2024 | 15 | +1 | 25.31M | $580.70M | +2 | −1 |
| Q2 2024 | 14 | n/a | 24.13M | $697.01M | n/a | n/a |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (pasivo) | 11.91M | -2.1% | $744.06M | 0.0% | ▼ Trim | 2 | SEC ↗ ×6 |
| 2 | BlackRock ✦ (pasivo) | 11.43M | +4.1% | $714.10M | 0.0% | ▲ Add | 2 | SEC ↗ ×21 |
| 3 | Baillie Gifford ✦ | 5.13M | +6.6% | $320.38M | 0.2% | ▲ Add | 6 | SEC ↗ ×4 |
| 4 | T. Rowe Price ✦ | 4.22M | +139.1% | $263.77M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 5 | Wellington Management ✦ | 3.25M | +69.0% | $203.00M | 0.0% | ▲ Add | 6 | SEC ↗ ×9 |
| 6 | Geode Capital Management ✦ (pasivo) | 2.94M | +0.6% | $183.51M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | State Street Global Advisors ✦ (pasivo) | 2.79M | -1.8% | $174.18M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 8 | Two Sigma Investments ✦ | 1.80M | -2.8% | $112.67M | 0.2% | ▼ Trim | 6 | SEC ↗ |
| 9 | Goldman Sachs Group ✦ | 1.51M | n/a | $94.11M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 10 | JPMorgan Chase ✦ | 987.64K | n/a | $61.71M | 0.0% | n/c | 1 | SEC ↗ ×20 |
| 11 | Morgan Stanley ✦ | 982.54K | n/a | $61.39M | 0.0% | n/c | 1 | SEC ↗ ×14 |
| 12 | Millennium Management ✦ | 878.58K | -67.7% | $54.89M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 13 | Fidelity (FMR) ✦ | 824.26K | -16.5% | $51.50M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 14 | ARK Investment Management ✦ | 795.23K | -71.8% | $49.69M | 0.3% | ▼ Trim | 6 | SEC ↗ |
| 15 | Renaissance Technologies ✦ | 531.85K | -21.2% | $33.23M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 304.52K | -89.6% | $19.03M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 17 | Marshall Wace ✦ | 241.31K | Nuevo | $15.08M | 0.0% | New | 1 | SEC ↗ ×2 |
| 18 | Adage Capital Partners ✦ | 152.12K | -50.5% | $9.50M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 19 | Point72 Asset Management ✦ | 102.42K | +81.9% | $6.40M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 81.58K | +1.8% | $5.10M | 0.0% | ▲ Add | 5 | SEC ↗ ×4 |
| 21 | D. E. Shaw & Co. ✦ | 33.35K | Nuevo | $2.08M | 0.0% | New | 1 | SEC ↗ |
| 22 | Bridgewater Associates ✦ | 4.01K | +3.6% | $250,545 | 0.0% | ▲ Add | 6 | SEC ↗ |
"Their weight" = la participación de la posición en el valor de renta variable 13F reportado por ese manager: la medida de convicción. ✦ = manager curado.
Nuevos compradores
| Marshall Wace | $15.08M | 0.0% |
| D. E. Shaw & Co. | $2.08M | 0.0% |
Posición cerrada
| Norges Bank | $64.14M | era 0.0% |
| PRIMECAP Management | $3.43M | era 0.0% |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 481 tenedores, 137.05M acciones, $11.53B declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué más suelen tener los titulares rastreados de este valor: recuentos de titularidad compartida, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Director · 116 acc. · $19,242
Director · 69 acc. · $11,032
Director · 1.10K acc. · $192,432
Director · 826 acc. · $144,550
Director · 3.30K acc. · $578,888
Director · 1.30K acc. · $229,236
Director · 971 acc. · $172,330
Director · 116 acc. · $20,300
Officer · 7.74K acc. · $1.38M
Officer · 4.00K acc. · $632,193
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología